Form 4: IRADIMED CEO Sells 5,000 Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on October 13, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, the CEO, President, Chairman, and a 10% owner of IRADIMED Corp, reported the sale of 5,000 shares of common stock.
• The transactions occurred on October 13, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• The shares were sold in multiple trades at weighted average prices of $72.16, $73.37, and $74.07.
• The sales were conducted indirectly through the Phillip Susi 2008 Dynasty Trust.
• Following these transactions, the Phillip Susi 2008 Dynasty Trust beneficially owns 2,337,500 shares.
• Other indirect holdings include 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with beneficial ownership disclaimed for the latter except for pecuniary interest.

Sentiment

Score: 5

Explanation: The sale of shares by a key insider, while reducing direct ownership, was conducted under a pre-arranged 10b5-1 trading plan, indicating a planned transaction rather than a reaction to new, adverse information. This mitigates potential negative sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction for diversification or liquidity rather than a reaction to new, adverse material information, which enhances transparency.

Negatives

• The reduction in direct insider ownership by a key executive (CEO, President, Chairman, and 10% owner) could be perceived negatively by some investors, despite being pre-planned.

Future Outlook

No forward-looking statements or guidance were provided in this insider transaction report.

Management Comments

• Roger E. Susi disclaims beneficial ownership of the 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.

Industry Context

This Form 4 filing is specific to an insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• The reported sales were conducted indirectly through the Phillip Susi 2008 Dynasty Trust.
• Other indirect holdings are reported through the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust.

Stakeholder Impact

• Shareholders may interpret the reduction in insider ownership differently, though the pre-planned nature of the sale under a 10b5-1 plan typically lessens concerns about management's confidence in the company's future.

Key Dates

Recommendation

The reported insider sales by CEO Roger E. Susi were executed under a pre-established Rule 10b5-1 trading plan, which suggests a planned diversification or liquidity event rather than a reaction to new material non-public information. While a reduction in insider ownership can sometimes be viewed negatively, the pre-planned nature mitigates this concern. Investors should monitor future filings and company performance for more comprehensive insights before making significant investment decisions.

Keywords

IRADIMED, IRMD, Roger Susi, insider trading, Form 4, stock sale, 10b5-1 plan, CEO, Director, 10% Owner